Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001062124 | SCV001226902 | uncertain significance | Cenani-Lenz syndactyly syndrome; Sclerosteosis 2; Congenital myasthenic syndrome 17 | 2022-09-07 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 1532 of the LRP4 protein (p.Val1532Leu). This variant is present in population databases (rs147609642, gnomAD 0.07%). This variant has not been reported in the literature in individuals affected with LRP4-related conditions. ClinVar contains an entry for this variant (Variation ID: 856623). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C25"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV001062124 | SCV002781705 | uncertain significance | Cenani-Lenz syndactyly syndrome; Sclerosteosis 2; Congenital myasthenic syndrome 17 | 2024-04-19 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004986791 | SCV005612833 | uncertain significance | Inborn genetic diseases | 2024-10-09 | criteria provided, single submitter | clinical testing | The c.4594G>C (p.V1532L) alteration is located in exon 31 (coding exon 31) of the LRP4 gene. This alteration results from a G to C substitution at nucleotide position 4594, causing the valine (V) at amino acid position 1532 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |